SequelSEC

CITIUS ONCOLOGY, INC. CTOR

Pharmaceutical Preparations · CIK 0001851484 · Fiscal year ends 0930

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-09-30
Operating income
-$23.52M
Fiscal year ended 2025-09-30
Free cash flow
Unavailable
Fiscal year ended 2025-09-30

CITIUS ONCOLOGY, INC. (CTOR) reported net income of -$24.76M for the fiscal year ended 2025-09-30. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from CITIUS ONCOLOGY, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CITIUS ONCOLOGY, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-12-312023-09-302022-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$23.52M-$20.57M-$1.01MUnavailable-$138.12K
Net income-$24.76M-$21.15M$2.42M-$12.70M$380.81K
Research & development$6.42M$4.93MUnavailable$4.24MUnavailable
Weighted-average diluted sharesshares 73.27Mshares 68.05Mshares 6.60Mshares 67.50Mshares 1.34M
Pretax income-$23.70M-$20.57MUnavailable-$12.12MUnavailable
Income tax expense$1.06M$576.00KUnavailable$576.00KUnavailable
Diluted EPS$-0.34$-0.31$0.27$-0.19$0.12
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$8.78M$8.15M$1.01M$5.92M$138.12K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CITIUS ONCOLOGY, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-12-312023-09-302022-12-31
Cash & equivalents$3.92M$112UnavailableUnavailableUnavailable
Total assets$100.94M$84.37M$72.62M$47.73M$68.19M
Current assets$27.54M$10.97M$58.20K$7.73M$377.34K
Total liabilities$56.08M$38.23MUnavailable$22.20MUnavailable
Current liabilities$49.49M$32.70M$2.05M$21.05M$31.84K
Total equity incl. NCI$44.87M$46.14M$22.73M$25.54M$345.51K
Temporary (mezzanine) equityUnavailableUnavailable$72.57M$70.63M$67.81M
Inventory$22.29M$8.27MUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$13.23M$3.71MUnavailable$1.29MUnavailable

Cash flow

CITIUS ONCOLOGY, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-12-312023-09-302022-12-31
Operating cash flow-$5.49M$126.35K-$601.30KUnavailable-$47.97K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$5.75M-$5.00M-$1.32MUnavailable-$67.32M
Financing cash flow$15.17M$4.87M$1.66MUnavailable$67.66M
Net change in cashUnavailableUnavailable-$256.43KUnavailable$289.18K
Stock-based compensation$8.32M$7.50MUnavailable$1.97MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

CITIUS ONCOLOGY, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302024-09-302023-12-312023-09-302022-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.56x0.34x0.03x0.37x11.85x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CTOR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-23View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-09-30

Difference 70627915 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.